A record number of commercialisation teams from Australian universities and research centres head to BIO 2005 this week focused on showcasing their offerings and cutting deals with US firms. Of the 63 Australian firms and organisations exhibiting at the Australia Pavilion, 20 of these are public and privately funded research centres.
Dr Anna Lavelle, the newly appointed Chief Executive Officer of AusBiotech, the Australian peak biotech industry organisation, said Australia has the IP and innovation and now needs to fast track commercialisation. She notes that there is no better place to target than the US which has led the world in commercialising innovation for decades. "We offer an exceptional range of opportunities for firms wanting to invest, partner and or license our biotech IP," she said.
Lavelle said Australia's strong IP protection, legal and social commonalities with the US and agreements like the Free Trade Agreement make doing business with Australian entities seamless and very profitable. "We often say it is just like working with another US firm," she said.
In addition, Australia is celebrating landmark research breakthroughs from stem cells and heart assist technology, to proteomics advances, carbohydrate chemistry, transdermal drug delivery, anti viral vaccines, inflammatory disease and cancer therapies, bio prospecting, skin therapies and ddRNAi /RNAi developments.
MEDICA.de; Source: AusBiotech